DGAP-News: Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd.
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Alliance
Evotec achieves milestone in drug discovery collaboration with Ono
Pharmaceutical Co., Ltd.
11.01.2013 / 07:29
---------------------------------------------------------------------
* Evotec receives a milestone payment from Ono for the progression of a
compound into pre-clinical development
Hamburg, Germany - 11 January 2013: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) today announced that a compound identified and optimised in a
research collaboration with Ono Pharmaceutical Co., Ltd. ('Ono') has been
nominated to enter pre-clinical development, leading to the payment of an
agreed milestone.
This collaboration project was initiated in March 2008. Evotec combined
high throughput screening and its proprietary fragment-based drug discovery
platform to identify novel compounds active against a protease target,
which were then further optimised with Ono to generate a candidate suitable
for pre-clinical development.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'We are
extremely pleased that we have collaborated with Ono Pharmaceutical on this
important project and delivered a pre-clinical candidate. The teams from
Ono and Evotec have enjoyed an excellent interaction and relationship
throughout the collaboration which has helped meet this goal. This
achievement clearly demonstrates the value we bring to our alliance
partners in the area of drug discovery. We look forward to continuing
working closely with our colleagues at Ono.'
'This pre-clinical candidate is an important member of our development
pipeline and we have high expectations for it. During the entire project we
could count on the access to various technologies and on the knowledge, but
in particular on the drug discovery expertise of our colleagues from
Evotec. They are an integrated part of our drug discovery strategy', said
Dr Kazuhito Kawabata, Managing Director, Research Headquarters at Ono.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in
the field of Alzheimer's disease. For additional information please go to
www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date ofthis report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Dr Mario Polywka, Chief Operating Officer, Phone: +44.(0)1235.441676,
mario.polywka(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
11.01.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
198816 11.01.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.01.2013 - 07:29 Uhr
Sprache: Deutsch
News-ID 218656
Anzahl Zeichen: 6968
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 342 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd."
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
